Priority industry for British business is and will be Russia's energy sector: if you the largest oil or gas company, you should be in Russia. Risks from work are high in Russia, and only on the income derived from work in energy sector justifies spent forces. One of the largest British companies involved in this business is BP International. BP operates on the Russian oil and gas market since the early 90-ies. In 1997, BP acquired a 10% stake in the oil company «SIDANKO», which at that time occupied the 4th place among the largest Russian oil corporations. In 2002, BP increased its stake in SIDANCO to 25% plus one share. In 2003 as a result of the unification of the Russian assets of BP and TNK, was established company TNK-BP. The company, which employs about 50,000 people, is represented in all major oil and gas regions of Russia.
For the period from 2003 to 2012, TNK-BP, the third largest vertically integrated oil and gas company in Russia, has received more than $55 billion of net profit. Production growth for nine years exceeded 40%, and total proved reserves (according to the classification of the securities Commission and US markets) in the period from 2003 to 2012 grew by more than 30%. High results of TNK-BP have been largely achieved thanks to the latest technologies and business processes, implemented with assistance of specialists from BP. Over its history, TNK-BP paid BP as a shareholder with about $19 billion of dividends, as well as more than $190 billion in taxes and duties to the budget of the Russian Federation. These results are a sign of successful joint work of BP with the professionals of the oil industry in Russia. Acquisition of a significant share of Rosneft shares, the world's largest public company in terms of production, allows BP to keep strong positions in the Russian market. The activity of BP in Russia is not limited to oil and gas projects. The contribution of BP in support of social, educational, cultural and charity projects is one of the most ambitious investment among foreign companies presented in Russia.
The second attractiveness industry for British business in Russia is the tobacco business. «British American tobacco» and «Gallagher» occupy a leading position in the tobacco market of Russia. Their investments in the tobacco factories of Moscow, St. Petersburg and Saratov exceed $ 700 million. In 2002, the BAT accounted for about 14% of the production of cigarettes in Russia. It owns three large factories - «Java» in Moscow, the tobacco factory in Saratov, and also a factory «Rothmans-Neva» in Saint-Petersburg. The equal share in Russian manufacture is owned by firm «Gallagher», which in 2000 acquired Moscow factory «Liggett-Dukat». The activities of the British tobacco companies on the Russian market is in a situation of overproduction of tobacco products. This intensifies competition between their producers. In these circumstances, the British Corporation spend considerable means for the promotion of their brands and development of the system of distribution of finished products. Simultaneously British companies increase their export from Russia. Among the 13 factories - exporters - «Liggett-Dukat», «BAT-Yava» and «Rothmans-Neva».
The third attractiveness of the industry for the British multinational companies is pharmaceuticals, which are presented by two «giants»: AstraZeneka and GlaxoSmithKline Plc. GlaxoSmithKline is one of the world's leading pharmaceutical companies. International company GlaxoSmithKline was formed by the merger of two major pharmaceutical companies, Glaxo Wellcome and SmithKline Beecham in January 2001, The company accounts about 5.3% of the global pharmaceutical market. GlaxoSmithKline takes leading positions by a number of developments in the field of immunization, and new drugs for the treatment of oncological diseases.Companies now included in GlaxoSmithKline, are present in the Russian market since the 1980s. Currently, the company is present in all regions of Russia, with representative offices in Moscow, Saint-Petersburg, Ekaterinburg, Rostov-On-Don, Novosibirsk, and its staff numbers more than 700 people. In Russia it is registered more than 120 drugs, representing a wide range of company medicines: antibacterial and antiviral drugs, including drugs against HIV-infection, cancer drugs, medicines for treatment of respiratory diseases, Central nervous system, gastrointestinal tract, metabolic disorders and vaccines.
«AstraZeneca», British Swedish pharmaceutical company, opened its representative office in 1999 in Russia. Today AstraZeneca Russia» - one of the most dynamic companies both in terms of growth in the number of patients receiving treatment with the use of its innovative products, and increased sales. The company has its representatives in 68 towns of Russia. About 40 original products of the company are registered and approved for use in the country. «AstraZeneca» offers physicians and patients in Russia modern high-quality drugs, whose effectiveness has been proved and confirmed in course of numerous clinical studies. The number of employees in Russia is about 1200. In promotion of their products «AstraZeneca» is guided by the highest ethical standards and does everything to provide doctors and patients with the most complete and reliable information about innovative approaches to treatment of socially significant diseases. Russia is one of the priority markets for AstraZeneca. Support of the Government of the Russian Federation on modernization of healthcare, «AstraZeneca» is making a significant contribution to the Russian economy. The overall contribution of AstraZeneca in the economy of the country within the nearest 5 years will amount to $1.2 billion This includes investments in production and R&D, training and development of employees and marketing opportunities, as well as in further development of new channels and information exchange technologies with the medical community. In 2011, the company announced the localization of production in Russia to increase the availability of innovative medicines for Russian patients. On the territory of Kaluga region, the construction of the pharmaceutical pharmaceutical factory of a full cycle, from preparation of medicinal forms to the packaging. In addition to the localization of production, «AstraZeneca» is realized in Russia large-scale projects in the field of support for research and development (R&D). As a socially responsible company, «AstraZeneca» is implementing a number of initiatives aimed at improving health and quality of life of patients, and also to raise awareness about socially significant diseases. Among these projects is the support of world Mental Health Day and the contest «achievements in the field of mental health, as well as participation in the unique national project «Your health - the future of Russia», which aims to increase the number of diagnosed patients with high cardiovascular risk, the increasing interest of the population to their health and to the early start of treatment.
